Taken together, the present findings suggest that enhanced endogenous ATP concentrations, via activation of purinergic receptors such as P2Y2R, might be causally related to the pathogenesis of antibody-mediated renal damage and might be a new target for the therapy of GN. The gene discussed is P2RY1; the disease is ganglioneuroma.